SCA
LXRX icon

SAC Capital Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

SAC Capital Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-3,971
Closed -$50K – 1880
2013
Q4 		$50K Buy
+3,971
New +$63.2K ﹤0.01% 1743

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SAC Capital Advisors's LXRX Position: Q1 2014 in Review

SAC Capital Advisors sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2014, closing a stake of 3,971 shares — an estimated $50K sold.

SAC Capital Advisors first reported a position in LXRX in Q4 2013 and held it in 1 quarter. The position peaked at $50K in Q4 2013. 103 funds tracked by Wall St. Rank hold LXRX as of Q1 2014.

  • SAC Capital Advisors reported no remaining Lexicon Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 3,971 Lexicon Pharmaceuticals shares in Q1 2014, an estimated $50K.
  • SAC Capital Advisors first reported a position in Lexicon Pharmaceuticals in Q4 2013 and held it in 1 quarter.
  • SAC Capital Advisors's Lexicon Pharmaceuticals position peaked at $50K in Q4 2013.
  • 103 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2014.

Based on SAC Capital Advisors's 13F filing for Q1 2014, filed 15 May 2014.